Daxor Corporation (NYSEMKT:DXR) Files An 8-K Amendment to Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 5.05 – On May 10, 2017 Eric Coleman, Chief Financial
Officer, was released from Daxor Corporation’s employ. On
Monday, May 15, 2017, John Wilkens assumed the role of Daxor’s
Chief Financial Officer.
About Daxor Corporation (NYSEMKT:DXR)
Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The Company engages in the short selling of stock. The Company maintains a diversified securities portfolio, which consists primarily of the common and preferred stocks of electric utility companies. It has approximately 70 Blood Volume Analyzers (BVA)-100. It also sells Volumex Kits. The semi-automated BVA provides blood volume measurements in human body, which are fundamental tools for diagnosis and treatment in a range of medical and surgical conditions, including congestive heart failure, hypertension, syncope, anemia in cancer patients, kidney failure and hyponatremia. The BVA-100 measures blood volume in approximately an hour. Its IDANT division provides semen banking services, which include anonymous donor semen and semen storage; autologous blood storage; andrology services, which include semen analysis and sperm washing, and general lab testing. Daxor Corporation (NYSEMKT:DXR) Recent Trading Information
Daxor Corporation (NYSEMKT:DXR) closed its last trading session 00.00 at 7.06 with 757 shares trading hands.
